NeoGenomics (NEO) Stock Price, News & Analysis

Company Overview

NeoGenomics, Inc. (NASDAQ:NEO) is a specialized oncology diagnostics company that provides testing services to hospitals, physicians, pathologists, pharmaceutical companies and other healthcare organizations. Its services support the diagnosis, classification and monitoring of cancer, helping guide treatment decisions and drug development.

The company offers a broad range of pathology and laboratory services, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, cytogenetics, flow cytometry, immunohistochemistry and digital pathology. NeoGenomics also provides clinical trial and biopharmaceutical services, including central laboratory testing, biomarker analysis and other support for oncology drug development programs.

Founded in 1999, NeoGenomics has expanded through organic growth and acquisitions into a network serving customers primarily in the United States, with additional international capabilities. The company operates specialized laboratories and supports testing across a variety of solid tumors and hematologic cancers. Its leadership includes President and Chief Executive Officer Chris Smith.

Key Stats

• Today's Range: $18.28 to $19.00
• 50-Day Range: $13.14 to $19.91
• 52-Week Range: $7.07 to $20.05
• Volume: 634,430 shs
• Average Volume: 2.25 million shs
• Market Capitalization: $2.44 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.67
• Consensus Rating: Moderate Buy

NeoGenomics Stock Analysis - MarketRank™

NeoGenomics scored higher than 20% of companies evaluated by MarketBeat, and ranked 804th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and 1 sell rating.

Downside Risk

NeoGenomics has a consensus price target of $17.67, representing about 6.3% downside from its current price of $18.86.

Amount of Analyst Coverage

NeoGenomics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NeoGenomics are expected to grow in the coming year, from ($0.09) to $0.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NeoGenomics is -47.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeoGenomics is -47.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeoGenomics has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.15% of the float of NeoGenomics has been sold short.

Short Interest Ratio / Days to Cover

NeoGenomics has a short interest ratio ("days to cover") of 11.18, which indicates bearish sentiment.

Change versus previous month

Short interest in NeoGenomics has recently increased by 6.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeoGenomics does not currently pay a dividend.

Dividend Growth

NeoGenomics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: -0.36

News Sentiment

NeoGenomics has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for NeoGenomics this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for NEO on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

5 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeoGenomics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.10% of the stock of NeoGenomics is held by insiders.

Percentage Held by Institutions

98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/28/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:NEO
• CIK: 1077183
• Web: www.neogenomics.com
• Phone: (239) 768-0600
• Fax: 239-690-4237
• Employees: 2,500
• Year Founded: 2002

Price Target and Rating

• Average Price Target for NeoGenomics: $17.67
• High Price Target: $25.00
• Low Price Target: $13.00
• Potential Upside/Downside: -6.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$108.03 million
• Net Margins: -6.77%
• Pretax Margin: -7.12%
• Return on Equity: -1.99%
• Return on Assets: -1.21%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 3.60
• Quick Ratio: 3.35

Sales & Book Value

• Annual Sales: $727.33 million
• Price / Sales: 3.33
• Cash Flow: $0.34 per share
• Price / Cash Flow: 55.13
• Book Value: $6.47 per share
• Price / Book: 2.92

Miscellaneous

• Outstanding Shares: 128,480,000
• Free Float: 127,062,000
• Market Cap: $2.43 billion
• Optionable: Optionable
• Beta: 1.79